MAXCYTE, INC.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

Unaudited Condensed Consolidated Statements of Cash Flow****s

(in thousands)


· · Three Months Ended March 31, ·
· · 2026 · · 2025 ·
Cash flows from operating activities: · · · ·
Net loss	$(4,750)	$(10,261)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,047	1,096
Lease right-of-use asset amortization	221	181
Net book value of consigned equipment sold	14	—
Loss on disposal of property and equipment	—	47
Stock-based compensation	1,141	3,039
Change in excess/obsolete inventory reserve	197	65
Amortization of discounts on investments	(437)	(884)

Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	(743)	(839)
Inventory	(380)	531
Prepaid expense and other current assets	69	65
Other assets	(127)	(254)
Accounts payable, accrued expenses and other	(3,637)	(5,589)
Operating lease liability	(456)	(278)
Deferred revenue	(327)	(1,326)
Other liabilities	(1)	(4)
Net cash used in operating activities	(8,169)	(14,411)

Cash flows from investing activities:
Purchases of investments	(25,122)	(34,645)
Maturities of investments	28,000	46,600
Purchases of property and equipment	(72)	(653)
Acquisition of intangible assets	(150)	—
Acquisition of business, net of cash acquired of $541	—	(1,773)
Net cash provided by investing activities	2,656	9,529

Cash flows from financing activities:
Proceeds from exercise of stock options	5	383
Net cash provided by financing activities	5	383
Net decrease in cash and cash equivalents	(5,508)	(4,499)
Cash and cash equivalents, beginning of period	20,065	27,884
Cash and cash equivalents, end of period	$14,557	$23,385

Supplemental cash flow information:
Property and equipment purchases included in accounts payable and accrued expenses	$24	$—
Right-of-use assets obtained in business combination by assumption of lease liabilities	$—	$956

MaxCyte, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(in thousands, except par value, share and per share amounts)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.